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INTRODUCTION
Refeeding syndrome (RFS) refers to the metabolic and clinical
changes that occur with rapid or excessive administration of feed-
ing, whether orally, enterally or parenterally, following a period of
relative or absolute starvation (1). RFS is characterized by fatal
complications such as heart failure, arrhythmia, respiratory failure
and cardiac arrest (2) ; thus, the prevention of RFS is vital. In gen-
eral, individuals with marasmus or kwashiorkor are at risk for RFS,
particularly in cases of greater than 10% weight loss over acouple of
months. Furthermore, patients are at risk after prolonged fasting,
massive weight loss in chronic alcoholism, prolonged intravenous
fluid repletion and anorexia nervosa (3, 4). Currently, this syn-
drome is common among elderly people with poor nutritional
intake due to alcoholism or dementia in the clinical practice.
Hypophosphatemia is the hallmark of RFS and is key to its pre-
vention and treatment (5). Further, it is reported to be associated
with increased mortality in critically ill patients (6, 7). The mecha-
nism of refeeding hypophosphatemia can be described by the fol-
lowing hypothesis. With the reintroduction of carbohydrates to
malnutrition patients, anabolism begins immediately and the body
shifts to carbohydrate metabolism from fat catabolism. The in-
creased glucose load, with a corresponding increase in the re-
lease of insulin, leads to cellular uptake of glucose, potassium (K),
magnesium (Mg), and phosphate (Pi). This shift of electrolytes
into the cell causes hypokalemia, hypomagnesemia, and hypo-
phosphatemia (8, 9). Patients consistently present with hypophos-
phatemia, although the other symptoms are not always detected.
However, the molecular mechanisms of hypophosphatemia and
RFS require elucidation.
RFS is more likely to occur after parenteral or enteral feeding
(10). In a study of patients that received total parenteral nutrition
(TPN), the incidence of hypophosphatemia ranged from 30-38%
when Pi was provided in the solution, to 100% when TPN without Pi
was administered (11). The RFS guideline of the National Institute
for Health and Clinical Excellence (NICE) in England and Wales
recommends that nutritional repletion of energy should be started
slowly, and Pi supplementation should be given unlessblood levels
are high before refeeding (12). Pi supplementation was reported to
reduce the incidence of hypophosphatemia in hospitalized patients
receiving TPN (13). Thus, Pi has an important role in RFS.
Guidelines on the prevention and treatment of this syndrome are
available ; however, cases continue to be seen clinically. One rea-
son why the mechanism of RFS is unknown is the lack of an ap-
propriate animal model. To our knowledge, there are no reports
of animal models with hypophosphatemia, making investiga-
tion of RFS challenging. Thus, the development of an animal
model is vital for the detailed evaluation of RFS as well as clarifica-
tion of its molecular mechanism. In this study, as a first step toward
revealing the mechanism of RFS, we attempted to develop an RFS
animal model using the TPN method with a high incidence of hypo-
phosphatemia in rats.
MATERIALS AND METHODS
Animals
Seven-week-old male Sprague-Dawley rats were obtained from
Japan SLC (Shizuoka, Japan). Rats were maintained on a 12 h
light-12 h dark cycles(9 : 00-21 : 00) with free access to water and
standard MF diet (Oriental Yeast, Tokyo, Japan). The experi-
mental procedure was approved by the ethics committee of the
University of Hyogo, School of Human Science and Environment.
The parenteral route was established under isoflurane anesthesia
ORIGINAL
Hypophosphatemia occurs with insulin administration during
refeeding by total parenteral nutrition in rats
Hiromi Kawamura1, Sarasa Tanaka2, Yuri Uenami2, Mariko Tani1, Midori Ishitani1, Saeko Morii2, Motoyoshi Sakaue1,
and Mikiko Ito1
1Graduate school of Human Science and Environment, 2School of Human Science and Environment, University of Hyogo, Hyogo, Japan
Abstract : Refeeding syndrome (RFS) is characterized by the metabolic and clinical changes that occur following
aggressive nutritional supplementation in malnourished patients. Hypophosphatemia is the hallmark of RFS
and is key to its prevention and treatment in clinical practice. However, the mechanism of hypophosphatemia
duringRFS is unclear because of the lack of an animalmodel. In this study, we developed a rat RFSmodel as a first
step to clarifying the molecular mechanism. After establishing the parenteral route, rats were fasted for 5 days
and refeeding was started using total parenteral nutrition. The animals were infused with a high calorie solution
with or without insulin administration. Results showed that plasma phosphate levels did not decrease in rats
infused with the high calorie solution alone ; in contrast, a 20% reduction compared to baseline was observed in
rats administered insulin. In addition, rats infused with the high calorie solution containing added phosphate did
not present with hypophosphatemia. Thus, we developed a rat RFS model with hypophosphatemia by tube feeding
and insulin administration, and demonstrated the importance of phosphate in preventing refeeding hypophos-
phatemia. J. Med. Invest. 65 : 50-55, February, 2018
Keywords : Refeeding syndrome, hypophosphatemia, total parenteral nutrition, animal model, insulin
Received for publication September 26, 2017 ; accepted October 16, 2017.
Address correspondence and reprint requests to Mikiko Ito, 1 -1 -12,
Shinzaike -Honcho, Himeji -city, Hyogo, 670-0092, Japan and Fax : +81-
79 -292-1515.
The Journal of Medical Investigation Vol. 65 2018
50
??
????
????? ?????
?????
???????? ?????
?????? ??????
?????????????????????? ????????? ?????
????
?? ??????????? ???????? ??????? ???????? ??????? ????????????????
using an anesthetizer (MT-AT200 ; Muromachi Kikai, Tokyo,
Japan). A silicon rubber tube (0.5 mm ID ; As-one, Osaka, Japan)
was inserted into the superior vena cava through the external
jugular vein and fixed according to the method of Steiger et al (14).
The tube was delivered to the skull subcutaneously and con-
nected to a swivel via a protective coil attached to the protective
harness (Quick connect infusion kit ; Bio Research Center, Nagoya,
Japan). The catheter was flushed with 50% heparin (Heparin
sodium 5,000 units/5 mL ; Mochida Pharmaceutical, Tokyo,
Japan) in saline every second day.
The experimental scheme is shown in Figure 1. Following sur-
gery, the rats were infused with TPN solution (Hicaliq RF ; Terumo,
Tokyo, Japan) at a rate of 4 mL/kg/h and given MF diet of approxi-
mately 30 kcal during the recovery period for 2 days. Following
recovery from surgery, rats were fasted and infused with lactated
Ringer’s solution (LRS, Solulact ; Terumo) for 5 days. Thereafter,
refeeding was started with TPN solution, and blood was collected
before and 2, 4, 6, 8, 10 and 12 hours after the start of refeeding.
Urine samples were collected for 12 hours (10 : 00-22 : 00) on feed-
ing period after operation, fasting period (fasting day 4) and re-
feeding period. The RF group (n=5) was infused with Hicaliq RF,
which is a glucose-based high calorie and Pi- free solution, during
refeeding (Table 1). The RF+I group (n=7) was infused with
Hicaliq RF for refeeding and injected with 0.75 U/kg of fast -acting
insulin (Humalog ; Eli Lily, Kobe, Japan) and 5 U/kg of long-
acting insulin (Insulin Glargine BSInj ; EliLily) before and 2 hours
after refeeding, respectively. The RFP+I group (n=4) was injected
with insulin in the same way as for the RF+I group, and Hicaliq RF
was supplemented with 10 mM Pi as KH2PO4 (dibasic potassium
phosphate injection 20 mEq kit ; Terumo) for use in refeeding.
Biochemical analysis
Plasma levels of Pi, Mg, calcium (Ca) and glucose were deter-
mined using the Phosphour C-test, Magnesium B-test, calcium E-
test and glucose CII- test Wako kits, respectively (Wako Pure
Chemical Industries, Osaka, Japan). Plasma insulin concentrations
were measured using a rat insulin enzyme-linked immunosorbent
assay (ELISA) kit (Morinaga Institute of Biological Science, Tokyo,
Japan). Urinary levels of Pi, Mg and creatinine (Cre) were meas-
ured. The measurement was requested to Hyogo Clinical Labora-
tory Corporation (Himeji, Japan).
Statistical analysis
The significance of differences between groups was assessed
using an analysis of variance followed by the Tukey-Kramer multi-
ple comparison test. Changesin body weight and biochemical pa-
rameters were evaluated by a paired t test. Data are presented as
the meanSEM and statistical significance was defined as p
0.05.
RESULTS
Establishment of RFS animal model
As a preliminary examination, we investigated the changes in
body weight and plasma Pi concentration during fasting for 3, 5
and 7 days. Results showed that the body weight of rats was re-
duced 17%, 23% and 30%, respectively, while plasma Pi levels were
significantly decreased at 5 and 7 days fasting (data not shown).
The NICE guideline indicates that individuals without nutritional
intake for5 days are at risk for RFS. Accordingly, the rats were
fasted for 5 days and showed more than a 20% reduction in body
weight. As water intake is decreased during food deprivation, the
rats were infused with LRS to prevent dehydration during fasting
(15). As a next step, we first attempted to refeed using ad libitum
Figure 1. Scheme of refeeding syndrome model
Table 1. Composition of TPN infusion
RF RFP LRS
Glucose (W/V%) 50 50 
Na (mEq/L) 50 50 131
K (mEq/L)  20 4
Ca2 (mEq/L) 6 6 3
Mg2 (mEq/L) 6 6 
Cl- (mEq/L) 30 30 110
Acetate- (mEq/L)   
L-Lactate- (mEq/L) 30 30 28
Gluconate- (mEq/L) 6 6 
Pi (mmol/L)  10 
Zn (µmol/L) 20 20 
Total energy (kcal/L) 2000 2000 
pH 4.0 -5.0 4.0 -5.0 6.0 -7.5
Osmotic pressure 11 11 0.9
LRS, lactated Ringer’s solution ; Na, sodium ; K, potassium ; Ca, calcium ;
Mg, magnesium ; Cl, chloride ; Pi, phosphate ; Zn, zinc.
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food intake in fasted rats (data not shown). Although the starved
rats refed, they did not have adequate food intake commensurate
with body weight by fasting for days. We also assessed refeeding
using forced oral administration of a high calorie solution ; how-
ever, the fasted rats showed intestinal atrophy, decreased intesti-
nal absorption and presented with diarrhea due to the high os-
motic pressure of the solution (data not shown). In light of these
challenges, we conducted refeeding using the TPN method, al-
lowing for a large infusion of glucose directly into the fasted rats.
In this study, we investigated three protocols of TPN infusion
during refeeding (Figure 1). Rats weighting about 230 g were used
for the operation, and they received high calorie infusion with TPN
and MF diet for the recovery of body weight following surgery. Two
days after surgery, the animals were largely recovered, and fasted
for 5 days. Next, refeeding was started. Rats were infused with high
calorie TPN solution alone in RF group. In RF+I group, rats were
infused with TPN solution and injected with insulin, and we defined
this group as the RFS model. In RFP+I group, rats were infused
TPN solution containing Pi and injected with insulin. We defined
this group as the Rescue model, which is capable of preventing
RFS. Body weight reduced more than 20% by fasting in all groups,
and there were no significant differences in body weight changes
between the groups (Table 2).
Changes in plasma levels during refeeding
Although we monitored biochemical parameters every 2 h com-
pared to baseline, the parameters became unstable soon after shift-
ing to refeeding (data not shown). In patient reports, refeeding
hypophosphatemia was observed at 48 h to 1 week depending on
the time required for metabolic changes (16). Hence, we showed
plasma levels from 6 to 12 h during refeeding, since they were
stable and possibly causative of hypophosphatemia.
Plasma glucose levels were elevated after refeeding in the RF
group (Figure 2A). Plasma Pi concentration decreased gradually
(Figure 2B) ; however, there were no significant differences com-
pared to the baseline (8.440.87 mg/dL at baseline vs 6.740.23
mg/dL at 12 h, p=0.07). PlasmaMg levels also didn’t change during
refeeding with TPN solution alone (Figure 2C). Plasma Ca levels
had no change during refeeding (6.740.30 mg/dL at baseline to
6.880.29 mg/dL at 12 h).
Insulin secretion in refeeding rats
Even though some rats in RF group presented with edema on the
face or arm following TPN administration, plasma Pi concentration
did not decrease significantly and plasma glucose concentration
maintained high levels (Figure 2). This may have been attribut-
able to low insulin secretion during fasting ; thus, we examined
plasma insulin levels in refeeding rats similar to RF group (Figure 3).
Although plasma glucose levels increased markedly, low levels of
plasma insulin were maintained in rats fasted for 5 days and infused
TPN solution (plasma insulin concentration increases 1.80.4 ng/
mL in normal fed rats after infusing glucose solution). Thus, we
next administered insulin to starved rats.
Development of hypophosphatemia following insulin injection
To induce RFS, rats were received TPN infusion and insulin
injection in RF+I group. Furthermore, to mimic the clinical treat-
ment of RFS, the rats were supplemented with Pi to prevent RFS in
RFP+I group. The TPN solution used in the latter group con-
tained 10 mM Pi, which is a common concentration used for
normal high calorie infusions that include Pi and K.
Plasma glucose levels were also increased in RF+I group, and
these increases were suppressed compared with RF group (Figure
4A). Further, plasma glucose levels also increased in the RFP+I
group (Figure 4D), and there were no significant differences be-
tween the RFS model and the Rescue model. Interestingly, plasma Pi
levels were significantly reduced at 10-12 h in the RF+I group
(7.210.47 mg/dL at baseline vs 5.820.47 mg/dL at 12 h, p
0.05), a 20% reduction compared to the baseline (Figure 4B). These
results suggested that the insulin injection caused hypophos-
phatemia during refeeding. In contrast to the RFS model, plasma Pi
levels did not decrease from the baseline in the Rescue model
(Figure 4E). Moreover, plasma Pi levels did not increase markedly
despite the continued Pi supplementation. This observation sup-
ports the case reports that Pi supplementation prevents refeeding
hypophosphatemia (11, 13). Although plasma Mg levels did not
change significantly in RF+I and RFP+I groups, the change indi-
cated different patterns between the two groups (Figure 4C, F).
Plasma Ca levels didn’t change during refeeding in these groups
Figure 2. Change in plasma levels during refeeding
RF group (A) plasma glucose, (B) Pi and (C) Mg levels. Values are
meansSEM.
Table 2. Change of body weight during TPN period
Body Weight (g) Operation Fasting start Refeeding start
RF 231.031.38 227.272.76 177.994.01**
RF+I 234.781.43 233.512.25 182.983.39**
RFP+I 232.475.08 235.576.52 170.262.24**
Values are the meanSEM. **p0.01 vs Fasting start
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even though addition of Pi for the Rescue model (6.280.36 mg/
dL at baseline to 6.470.16 mg/dL at 12 h in RF+I group, and
7.060.22 mg/dL at baseline to 6.770.32 mg/dL at 12 h in
RFP+I group).
Mineral excretions during refeeding
We determined urinary excretions of Pi and Mg during refeed-
ing in order to confirm a decrease of plasma mineral level was not
induced by kidney excretion. Urinary Pi levels did not increase dur-
ing refeeding compared with feeding or fasting period in the RFS
model and the Rescue model (Figure 5A). Urinary Mg excretions
also did not change significantly in both groups (Figure 5B). This
finding showed that refeeding hypophosphatemia was caused by
increased cellular Pi uptake in vivo.
DISCUSSION
We demonstrated that plasma Pi levels reduced following insulin
injection in refeeding rats with TPN and the hypophosphatemia
was ameliorated by Pi supplementation. This suggests that our rat
model reflects RFS in hospitalized patients. To our knowledge, this is
the first study to report the development of an RFS animal model. In
addition, we also created a rescue model according to the treatment
guidelines.
Several studies have reported that hospitalized subjects with
severe malnutrition, i.e., loss of body weight over a short period, low
Figure 3. Insulin secretion in refeeding rats
(A) Plasma glucose and (B) plasma insulin levels in refeeding rats
similar to RF group. Values are meansSEM.*p0.05 vs baseline by a
paired t test.
Figure 4. Effect of insulin injection on plasma levels during refeeding
RF+I group (A) plasma glucose, (B) Pi and (C) Mg levels (gray circle). RFP+I group (D) plasma glucose, (E) Pi and (F) Mg levels (black
circle). Values are meansSEM. *p0.05 vs baseline by a paired t test.
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body mass index16 kg/m2 or poor nutritional intake for weeks,
developed refeeding hypophosphatemia (17-19). In addition, it
was reported that serum Pi levels decreased after about 2 days of
refeeding (16). In the present study, rats were fasted for 5 days
(resulting in 20% loss of body weight) and developed hypophos-
phatemia at 12 hours after rapid tube feeding. Furthermore, some
RFS model rats showed a reduced breathing rate, edema and a
decline in activity after beginning the high calorie infusion, while
the Rescue model rats did not show the same degree of those symp-
toms (data not shown). In general, blood Pi levels in rat is higher
than human so that it is difficult to determine how much reduction is
hypophosphatemia in animal. However, our RFS model had a re-
duction of plasma Pi levels and the symptoms as mentioned above.
Therefore, we confirmed refeeding hypophosphatemia was caused
not by renal excretion but by Pi consumption in vivo. These results
suggest that this rat model reflects refeeding hypophosphatemia in
malnutrition patients receiving aggressive nutrition therapy.
We infused rats with TPN solution at a rate of 4 mL/kg/h in
reference to the experimental animal administration guidelines of
the European Federation of Pharmaceutical Industries Associations
and the European Centre for the Validation of Alternative Methods
(20). Other studies in rats used TPN solution containing a fat or
protein source, with 270 kcal/kg/day being administered (21).
However, we infused 192 kcal/kg/day to rats using a glucose-
based high calorie infusion without fat or amino acids to generate
RFS. Although this amount of energy might be insufficient for
RFS development, it is conceivable that our glucose dosage was
sufficient to promote refeeding hypophosphatemia in light of previ-
ous reports of the effects of reintroduction of carbohydrates in this
syndrome (22). Some reports have demonstrated RFS in animals ;
however, symptoms appeared after several days (23, 24). Because of
the direct infusion of glucose solution via intravenous administra-
tion, we were able to observe hypophosphatemia within one day.
The pathophysiology of RFS is thought to involve the stimula-
tion of insulin release, resulting in anabolic activity and a shift of
electrolytes into the cell. We generated hypophosphatemia in TPN-
fed rats following insulin injection ; however, plasma Pi levels did
not decline significantly during refeeding in the absence of insulin.
Furthermore, not only plasma Pi levels but also plasma Mg levels
reduction was observed in our RFS model. This result demon-
strates that the presence of insulin triggers the development of
hypophosphatemia during refeeding. Since insulin activates ATPase
(25), increasing insulin concentrations might stimulate Pi con-
sumption for ATP generation, which is essential for energy produc-
tion. Namazi et al. reported that refeeding after starvation de-
creased serum K and Pi concentrations, increased insulin levels
and altered the hepatic histopathology in rats (24). The effect of
changes in glucose or lipid metabolism on liver tissues may be
associated with insulin-stimulated Pi consumption. In present
study, we administered insulin during refeeding because of low
insulin secretion in starved rats. However, serum insulin levels in
patients identified as at-risk are not measured in the clinical
practice. As such, it may be necessary to investigate changes in
insulin levels in RFS patients, and the monitoring of insulin levels
in at -risk patients may be necessary to prevent refeeding hypo-
phosphatemia in the future. In addition, a previous study revealed
that refeeding with glucose induced the gene expression of acute
liver inflammation markers and hepatocyte destruction in mice
(26). Acute metabolic changes involved in hepatic inflammation
are also thought to have a high requirement for minerals during
refeeding.
The NICE guidelines outline the prevention and treatment of
RFS, specifically focusing on start with hypocaloric nutritional
intake and the supplementation of electrolytes in the clinical setting
(27). In this context, we were able to prevent refeeding hypophos-
phatemia by Pi administration, indicating the importance of Pi in
energy metabolism during refeeding. In addition, the absence of
increased urinary Pi also supported Pi was required in vivo on re-
feeding. Optimization of the supplementation protocol, such as the Pi
source, timing of infusion, and effective dose, should be investi-
gated in a future study.
We created an RFS model in order to clarify the mechanism of
refeeding hypophosphatemia in rats. This model enables the investi-
gation of the state of RFS in more detail as well as its molecular
mechanisms. Following insulin injection associated with hypo-
phosphatemia, plasma Mg levels showed a decrease from baseline
(2.560.19 mg/dL at baseline vs 2.310.28 mg/dL at 12 h, p=
0.072) even though there was no significant difference in the RFS
model. This result might to be because rats were infused TPN
solution containing Mg2 (6 mEq/dL). On the other hand, plasma
Mg levels did not change in the rescue model. Consequently, we
should examine the difference in plasmaMg concentrations by
with or without Pi during refeeding. Vitamin or mineral deficien-
cies, such as K or thiamine, have been reported for RFS. Moreover,
alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) levels were altered in RFS (28). It is therefore necessary to
investigate levels of other minerals and hepatic function in our RFS
model.
Figure 5. Urinary excretion of Pi and Mg with insulin injection
Urine were collected for 12 hours on feeding, fasting and refeeding period in RF+I group (gray bars) and RFP+I group (black bars). (A) Urinary Pi/
urinary Cre and (B) urinary Mg/ urinary Cre. Values are meansSEM.
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In conclusion, we are the first to report the establishment of an
animal model of RFS using tube feeding. This is the first step in
determining the mechanism of RFS. We also showed the impor-
tance of Pi in preventing refeeding hypophosphatemia. Further
study is needed to examine the molecular mechanism of RFS using
our rat model.
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